CN102573893A - IL-1β抗体及其结合片段的心血管相关用途 - Google Patents

IL-1β抗体及其结合片段的心血管相关用途 Download PDF

Info

Publication number
CN102573893A
CN102573893A CN2010800330317A CN201080033031A CN102573893A CN 102573893 A CN102573893 A CN 102573893A CN 2010800330317 A CN2010800330317 A CN 2010800330317A CN 201080033031 A CN201080033031 A CN 201080033031A CN 102573893 A CN102573893 A CN 102573893A
Authority
CN
China
Prior art keywords
antibody
binding
individual
fragment
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800330317A
Other languages
English (en)
Chinese (zh)
Inventor
P·J·斯加侬
A·M·索林格
J·D·菲尔德施泰因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma US LLC
Original Assignee
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd USA filed Critical Xoma Technology Ltd USA
Priority to CN201710537454.6A priority Critical patent/CN107243077A/zh
Publication of CN102573893A publication Critical patent/CN102573893A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2010800330317A 2009-05-29 2010-05-28 IL-1β抗体及其结合片段的心血管相关用途 Pending CN102573893A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710537454.6A CN107243077A (zh) 2009-05-29 2010-05-28 IL‑1β抗体及其结合片段的心血管相关用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18267909P 2009-05-29 2009-05-29
US61/182,679 2009-05-29
US25257109P 2009-10-16 2009-10-16
US61/252,571 2009-10-16
US31300110P 2010-03-11 2010-03-11
US61/313,001 2010-03-11
PCT/US2010/036761 WO2010138939A1 (en) 2009-05-29 2010-05-28 CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710537454.6A Division CN107243077A (zh) 2009-05-29 2010-05-28 IL‑1β抗体及其结合片段的心血管相关用途

Publications (1)

Publication Number Publication Date
CN102573893A true CN102573893A (zh) 2012-07-11

Family

ID=43223130

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800330317A Pending CN102573893A (zh) 2009-05-29 2010-05-28 IL-1β抗体及其结合片段的心血管相关用途
CN201710537454.6A Pending CN107243077A (zh) 2009-05-29 2010-05-28 IL‑1β抗体及其结合片段的心血管相关用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710537454.6A Pending CN107243077A (zh) 2009-05-29 2010-05-28 IL‑1β抗体及其结合片段的心血管相关用途

Country Status (15)

Country Link
US (3) US20100316651A1 (https=)
EP (1) EP2435073A4 (https=)
JP (2) JP5763625B2 (https=)
KR (1) KR20120061041A (https=)
CN (2) CN102573893A (https=)
AU (1) AU2010253924B2 (https=)
BR (1) BRPI1011228A2 (https=)
CA (1) CA2763161A1 (https=)
EA (1) EA201101643A1 (https=)
HK (1) HK1245111A1 (https=)
IL (1) IL216660A0 (https=)
MX (1) MX2011012666A (https=)
NZ (1) NZ597024A (https=)
SG (3) SG176265A1 (https=)
WO (1) WO2010138939A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103059136A (zh) * 2012-12-24 2013-04-24 浙江大学 抗中华鳖IL-1β多克隆抗体的制备及在检测中的应用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832066C (en) * 2011-04-01 2023-04-18 The Medicines Company Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage
BR112014007253A2 (pt) * 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
ES2534782T3 (es) * 2012-02-02 2015-04-28 Baylor College Of Medicine Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis
CN103588878A (zh) * 2012-08-15 2014-02-19 江苏泰康生物医药有限公司 一种人源化抗人白细胞介素1 β单克隆抗体及其制备与应用
CN113018431A (zh) * 2012-10-04 2021-06-25 詹森生物科技公司 治疗血管疾病及其并发症
AU2013344796B2 (en) * 2012-11-16 2016-11-10 Novartis Ag Use of IL-1 beta binding antibodies for treating peripheral arterial disease
US10000557B2 (en) * 2012-12-19 2018-06-19 Dnae Group Holdings Limited Methods for raising antibodies
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
EP3965819A4 (en) * 2019-05-03 2023-07-12 University of Zürich TREATMENT OF CEREBRAL ISCHEMIA-REPERFUSION INJURY
US20220275079A1 (en) * 2020-11-20 2022-09-01 The General Hospital Corporation Clonal Hematopoiesis and Risk of Chronic Liver Disease
GB202400340D0 (en) 2024-01-10 2024-02-21 Wotherspoon Hugh Robert IL-1B binding antibody

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637873A (en) * 2005-01-26 2006-11-01 Abgenix Inc Antibodies against interleukin-1 beta
WO2007002261A2 (en) * 2005-06-21 2007-01-04 Xoma Technology Ltd. IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
CN101356286A (zh) * 2005-11-17 2009-01-28 英特利金遗传学有限公司 心血管病症的诊断和疗法
US7662772B2 (en) * 1999-04-23 2010-02-16 Acorda Therapeutics, Inc. Methods for treating congestive heart failure

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR016551A1 (es) * 1997-07-30 2001-07-25 Smithkline Beecham Corp Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
US7860583B2 (en) * 2004-08-25 2010-12-28 Carefusion 303, Inc. System and method for dynamically adjusting patient therapy
CA2440387A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US20040106954A1 (en) * 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
US20060171948A1 (en) * 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
WO2006084145A2 (en) * 2005-02-02 2006-08-10 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to reduce c-reactive protein
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
US20100015146A1 (en) 2005-10-14 2010-01-21 Novo Nordisk A/S Treating diabetes using inhibitors of il-1
JP4524275B2 (ja) * 2006-09-01 2010-08-11 日本ポリプロ株式会社 ビニル基および極性基含有プロピレン系共重合体及びそれを用いる重合体の製造方法。
CA2673592C (en) * 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662772B2 (en) * 1999-04-23 2010-02-16 Acorda Therapeutics, Inc. Methods for treating congestive heart failure
TW200637873A (en) * 2005-01-26 2006-11-01 Abgenix Inc Antibodies against interleukin-1 beta
WO2007002261A2 (en) * 2005-06-21 2007-01-04 Xoma Technology Ltd. IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
CN101228188A (zh) * 2005-06-21 2008-07-23 佐马技术有限公司 IL-1β结合抗体及其片段
CN101356286A (zh) * 2005-11-17 2009-01-28 英特利金遗传学有限公司 心血管病症的诊断和疗法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GILES TD ET AL.,: ""Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations"", 《CARDIOL CLIN》 *
KAVSAKA ET AL.,: ""Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure"", 《CLINICAL BIOCHEMISTRY 》 *
MAY H.T. ET AL.,: ""Homocysteine levels are associated with increased risk of congestive heart failure in patients with and without coronary artery disease"", 《CARDIOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103059136A (zh) * 2012-12-24 2013-04-24 浙江大学 抗中华鳖IL-1β多克隆抗体的制备及在检测中的应用

Also Published As

Publication number Publication date
MX2011012666A (es) 2011-12-16
US20210009679A1 (en) 2021-01-14
KR20120061041A (ko) 2012-06-12
WO2010138939A1 (en) 2010-12-02
IL216660A0 (en) 2012-02-29
CA2763161A1 (en) 2010-12-02
CN107243077A (zh) 2017-10-13
AU2010253924A1 (en) 2012-01-19
SG10201500180RA (en) 2015-03-30
JP5763625B2 (ja) 2015-08-12
NZ597024A (en) 2014-01-31
SG2014014534A (en) 2014-07-30
JP2012528796A (ja) 2012-11-15
JP2015120704A (ja) 2015-07-02
US20100316651A1 (en) 2010-12-16
AU2010253924B2 (en) 2015-01-22
SG176265A1 (en) 2012-01-30
EP2435073A1 (en) 2012-04-04
HK1245111A1 (zh) 2018-08-24
US10611832B2 (en) 2020-04-07
US20180155420A1 (en) 2018-06-07
BRPI1011228A2 (pt) 2019-09-24
EP2435073A4 (en) 2013-03-27
EA201101643A1 (ru) 2012-12-28

Similar Documents

Publication Publication Date Title
US10611832B2 (en) Cardiovascular related uses of IL-1β antibodies and binding fragments thereof
US20210032326A1 (en) Methods for the treatment of gout
ES2398693T3 (es) Métodos para el tratamiento de la artritis reumatoide
US9139646B2 (en) Methods for the treatment of uveitis with IL-1β binding antibodies
AU2013203560A1 (en) Cardiovascular related uses of IL-1beta antibodies and binding fragments thereof
AU2015203141A1 (en) Methods for the treatment of gout
AU2013203214A1 (en) Methods for the treatment of IL-1ß related conditions
AU2011249854A1 (en) Methods for the treatment of IL-1beta related conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: XOMA US LLC

Free format text: FORMER OWNER: XOMA TECHNOLOGY LTD.

Effective date: 20140605

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140605

Address after: American California

Applicant after: XOMA US LLC

Address before: American California

Applicant before: Xoma Technology Ltd.

RJ01 Rejection of invention patent application after publication

Application publication date: 20120711

RJ01 Rejection of invention patent application after publication